Drug development for the treatment of Alzheimer’s disease
Targeting diseases at their molecular root
Vivoryon Therapeutics is a biopharmaceutical company engaged in the research and development of novel therapeutic products, primarily for the treatment of Alzheimer’s disease. Vivoryon has identified a novel therapeutic concept related to disease initiation and progression. The development approach focusses on pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to target Alzheimer’s disease.